Heparanase is an endoglycosidase involved in remodeling the extracellular matrix and
thereby in regulating multiple cellular processes and biological activities. It cleaves heparan …

The heparan sulfate (HS) mimetic PI-88 is a promising inhibitor of tumor growth and
metastasis expected to commence phase III clinical evaluation in 2007 as an adjuvant …

Beyond anticoagulation, the therapeutic potential of heparin derivatives and heparan sulfate
(HS) mimetics (functionally defined HS mimetics) in oncology is related to their ability to bind …

Sulfated polysaccharides are ubiquitous in living systems and have central roles in
biological functions such as organism development, cell proliferation and differentiation …

The heparan sulfate mimetic PI-88 (muparfostat) is a complex mixture of sulfated
oligosaccharides that was identified in the late 1990s as a potent inhibitor of heparanase. In …

Purpose: PI-88 is a mixture of highly sulfated oligosaccharides that inhibits heparanase, an
extracellular matrix endoglycosidase, and the binding of angiogenic growth factors to …

The binding interactions of the phosphosulfomannan anticancer agent PI-88 (1) with the
angiogenic growth factors FGF-1, FGF-2, and VEGF were studied by surface plasmon …

The β-D-endoglycosidase heparanase has been proposed to be important in the
pathogenesis of proteinuria by acting to selectively degrade the negatively charged side …

Targeting heparan sulfate proteoglycans (HSPGs) and enzymes involved in heparan sulfate
(HS) chain editing is emerging as a new anticancer strategy. The involvement of HSPGs in …

The phosphosulfomannan 1 (PI-88) is a mixture of highly sulfated oligosaccharides that is
currently undergoing clinical evaluation in cancer patients. As well as its anticancer …